http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-067530-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b6042509de7544921c96de43b9da1438 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 |
| filingDate | 2008-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8dc913d8981058b2c6a5d11b61136245 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2d3406fe224e3d477a80bfb757114f11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f8f5693f93a3d519a5ea26f302739df6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce90562a1ed3f15e48f2c647c26bdd69 |
| publicationDate | 2009-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-067530-A1 |
| titleOfInvention | DERIVATIVES OF 6- PHENYL-1H- IMIDAZO (4,5-C) PIRIDINA -4- CARBONITRILE |
| abstract | This is related to the 6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives having the general formula (1) derivatives of formula (1) the pharmaceutical compositions that comprise them both with use of these derivatives for the preparation of a medicament for the treatment of diseases related to cathepsin S such as atherosclerosis, obesity, inflammation, immune disorders, such as rheumatoid arthritis, psoriasis, cancer, and chronic pain. Claim 1: A 6-phenyl-1H-imidazo [4,5-e] pyridine-4-carbonitrile derivative having the general (1) characterized in that R1 is H or C1-3 alkyl; R2 is H or C1-3 alkyl; R3 is halogen or C1-4 alkyl, optionally substituted by one or more halogens; R4 is H, halogen or CN; X is C2, O or S; n is 1-5; Y is selected from OH, CN, C 1-3 alkylcarbonyl, NR5R6 and Z, where Z is a saturated heterocyclic ring of 5 or 6 elements containing 1-3 heteroatoms selected from O, S and NR7, the ring of which can be substituted by OH , oxo, C1-3 alkyl, C1-3 hydroxyalkyl or C1-3 alkoxyalkyl; or where Z is an aromatic heterocyclic ring of 5 or 6 elements containing 1-3 heteroatoms selected from O, S and N, the ring of which may be substituted by OH, C1-3 alkyl or C1-3 hydroxyalkyl; R5 and R6 are independently H, C3-8 cycloalkyl or C1-6 alkyl, optionally substituted by halogen, OH, CF3, C3-8 cycloalkyl, C1-6oxy alkyl, CONR14R15, NR14R15, SO2R16, a heteroaryl group of 5 or 6 elements containing 1-3 heteroatoms selected from O, S and N, or a saturated heterocyclic group of 5 or 6 elements containing a heteroatom selected from O, S or NR8; or R5 and R6 together with the N to which they are attached form a saturated heterocyclic ring and 4-10 elements, optionally also comprise 1-3 heteroatoms selected from O, S and NR9, the ring being optionally substituted by OH, oxo, alkyl C1-4, hydroxy C1-3 alkyl, C3-8 cycloalkyl, CONR10, R11 or NR10, R11; R7 is H, C1-3 alkyl or C1-3 hydroxyalkyl; R8 is H, C1-3 alkyl or C1-3 hydroxyalkyl; R9 is H, C1-3 alkyl, C3-7 cycloalkyl, C1-3 hydroxyalkyl, C1-3 alkoxy-C1-3 alkyl, C1-6 alkylcarbonyl, C1-6 alkyloxycarbonyl, CONR12R13, C2CONR12R13 or a heteroaryl group of 5 or 6 elements containing 1-3 heteroatoms selected from O, S and N; R10 and R11 are independently H or C1-3 alkyl; R12 and R13 are independently H or C1-3 alkyl; or R12 and R13 together with the nitrogen to which they are attached form a saturated heterocyclic ring of 4-8 elements, optionally further comprising a heteroatom selected from O and S; R14 and R15 are independently H or C1-3 alkyl; or R14 and R15 together with the nitrogen to which they are attached form a saturated heterocyclic ring of 4-8 elements, optionally further comprising a heteroatom selected from O and S; R16 is (C13) alkyl; or a pharmaceutically acceptable salt thereof. |
| priorityDate | 2007-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 46.